Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12497446 | 0.94 | CPB1 (0.36) | SIRT1CPB1CPB2CA1CA2 | |
| SCHEMBL13367216 | 0.93 | SIRT5 (0.33) | SIRT1CPB1CPB2CA1CA2 | |
| SCHEMBL10066896 | 0.92 | CPB1 (0.32) | SIRT1CPB1CPB2CA1CA2 | |
| SCHEMBL2610729 | 0.92 | SIRT2 (0.35) | SIRT1CPB1CPB2CA1CA2 | |
| SCHEMBL10310593 | 0.88 | SIRT2 (0.41) | SIRT1CPB1CPB2SIRT5SIRT2 | |
| SCHEMBL12509123 | 0.84 | SIRT1 (0.34) | SIRT1CPB1CPB2SIRT6 | |
| SCHEMBL20010470 | 0.82 | SIRT2 (0.39) | SIRT1CPB1CPB2SIRT5SIRT2 | |
| SCHEMBL14016183 | 0.81 | AKT1 (0.40) | SIRT1CPB1CPB2CA1CA2 | |
| SCHEMBL11955676 | 0.80 | SIRT2 (0.37) | SIRT1CPB1CPB2SIRT5SIRT2 | |
| SCHEMBL10026185 | 0.78 | AKT1 (0.39) | SIRT1CA1CA2EPHX1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085629-B2 | Compositions monovalent for CD28 binding and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130216538-A1 | Compositions and Methods for Treating Inflammatory Disorders | DOMANTIS LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130109846-A1 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE | DOMANTIS LTD. (GB) | 2013-05-02 | — | — | US | disclosed |
| US-8293869-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120244597-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-09-27 | — | — | US | disclosed |
| US-8273339-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2012-09-25 | — | — | US | disclosed |
| US-8247536-B2 | Factor VIII compositions | NEKTAR THERAPEUTICS (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-8133977-B2 | Polymer-factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130427-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | SIRT1 4665/4885CPB1 232/4885CPB2 219/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SIRT1 4441/4885CPB1 158/4885CPB2 137/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | SIRT1 3908/4885CPB1 334/4885CPB2 383/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | SIRT1 3698/4885CPB1 1842/4885CPB2 1529/4885 |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT1 3966/4885CPB1 277/4885CPB2 338/4885 |
| US-20130216538-A1 | Compositions and Methods for Treating Inflammatory Disorders | TNF, IL5, C5 | SIRT1 4294/4885CPB1 1219/4885CPB2 687/4885 |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SIRT1 4220/4885CPB1 216/4885CPB2 213/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT1 3966/4885CPB1 277/4885CPB2 338/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | SIRT1 3828/4885CPB1 986/4885CPB2 1252/4885 |
| US-20130109846-A1 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE | CD69, CD40LG, CD40 | SIRT1 2947/4885CPB1 3311/4885CPB2 3987/4885 |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT1 3966/4885CPB1 277/4885CPB2 338/4885 |
| US-20100130427-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SIRT1 4382/4885CPB1 201/4885CPB2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.